Results 111 to 120 of about 12,515 (211)

A rare complication of imatinib mesylate therapy: drug-induced pneumonitis

Терапевтический архив, 2010
The use of imatinib mesylate (Glivec®) (Novartis Pharma AG, Switzerland) that is the drug of choice in treating patients with chronic myeloid leukemia (CML) has increased 7-year survival and improved the prognosis of the disease.
Ol'ga Veniaminovna Stakhina, A G Turkina, I E Kostina, Yu B Kochkareva, O V Stakhina, A G Turkina, I E Kostina, Yu B Kochkareva   +7 more
doaj  

Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome [PDF]

, 2003
Jorge E. Cortés, Patricia Ault, Charles Koller, Deborah Thomas, Alessandra Ferrajoli, William G. Wierda, Mary Beth Rios, Laurie Letvak, Elizabeth S. Kaled, Hagop M. Kantarjian   +9 more
openalex   +1 more source

Modulation of Plasma 25-Hydroxyvitamin D3 Level by Imatinib Mesylate in Patients with Chronic Myelogenous Leukemia: The Role of Uptake and Efflux Transporters. [PDF]

Curr Ther Res Clin Exp, 2022
Omran MM, Shouman SA, Abdelfattah R, Moussa HS, Thabet NA, Hamza MS.   +5 more
europepmc   +1 more source

Inhibition of bcr-abl gene expression by small interfering RNA sensitizes for imatinib mesylate (STI571) [PDF]

, 2003
Lara Wohlbold, Heiko van der Kuip, Cornelius Miething, Hans‐Peter Vornlocher, Cornelius Knabbe, Justus Duyster, Walter E. Aulitzky   +6 more
openalex   +1 more source

Imatinib Mesylate Reduces Neurotrophic Factors and pERK and pAKT Expression in Urinary Bladder of Female Mice With Cyclophosphamide-Induced Cystitis. [PDF]

Front Syst Neurosci, 2022
Perkins M, Girard BM, Campbell SE, Hennig GW, Vizzard MA.   +4 more
europepmc   +1 more source

Results of Multicenter Phase II Study With Imatinib Mesylate in Allogeneic Recipients With Steroid-Refractory Chronic GVHD. [PDF]

Cell Transplant, 2022
Baek DW, Cho HJ, Kim JH, Ahn JS, Kim HJ, Lim SN, Cheong JW, Kim SY, Lee HS, Won JH, Yhim HY, Sohn SK, Moon JH.   +12 more
europepmc   +1 more source

Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome–positive chronic myelogenous leukemia treated with interferon‐α regimens for early chronic phase [PDF]

, 2003
Hagop M. Kantarjian, Susan O’Brien, Jorge E. Cortés, Jianqin Shan, Francis J. Giles, Guillermo Garcia‐Manero, Srđan Verstovšek, Stefan Faderl, Mary Beth Rios, Moshe Talpaz   +9 more
openalex   +1 more source

Dynein axonemal heavy chain 9 M4374I variation may have an effect on imatinib mesylate resistance in CML. [PDF]

Med Int (Lond), 2022
Yildirim MS, Şi Mşek L, Zamani AG, Çeneli Ö, Demi Rci Oğlu SN.   +4 more
europepmc   +1 more source

Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment [PDF]

, 2003
Ravi Bhatia, Melissa Holtz, Ning Niu, Rachel Gray, David S. Snyder, Charles L. Sawyers, Daniel A. Arber, Marilyn L. Slovak, Stephen J. Forman   +8 more
openalex   +1 more source

Results of TETimaX Trial of Langerhans Cell Histiocytosis Treatment and Perspectives on the Role of Imatinib Mesylate in the Era of MAPK Signaling. [PDF]

Biomedicines, 2021
Montella L, Ottaviano M, Riccio V, Picozzi F, Facchini G, Insabato L, Giuliano M, Palmieri G.   +7 more
europepmc   +1 more source